Morbidly adherent placenta (MAP) is characterized by abnormal placental implantation and invasion of chorionic villi into the uterine myometrium leading to incomplete separation or non-separation of placenta from the uterine wall during labor. It is one of the most serious pregnancy complications that may lead to post-partum hemorrhage, uterine perforation, and infection(1).
MAP remains undiagnosed before delivery in one-half to two-thirds of all cases. The prenatal diagnosis of MAP is vital to prevent the associated maternal and neonatal morbidity and mortality, and to perform appropriate risk assessment and adequately plan for delivery(2). The incidence of MAP is rapidly increasing along with the upward trend in cesarean delivery, which is proposed as a major risk factor for MAP in subsequent deliveries(3,4).
The first-line imaging modality for screening and diagnosing MAP is ultrasound evaluation, which is used routinely because of its low cost and wide availability; however, its diagnostic criteria and accuracy are still under investigation(5,6). Magnetic resonance imaging (MRI) has also shown high sensitivity and specificity in predicting MAP and can be used as an additional effective modality for cases with inconclusive ultrasound findings(6).
According to a meta-analysis, ultrasound criteria, including the loss of subendometrial echolucent zone or the presence of abnormal placental lacunae, were highly sensitive and specific when performed by skilled operators(7). The predictive value of ultrasound criteria has been assessed in several studies(5,6,8); however, there is not enough evidence for the sensitivity and specificity of quantitative ultrasound findings in detecting MAP.
Placental lacunae are defined as vascular structures with different sizes and shapes in placental parenchyma, and have been proposed as one of the primary indicators of MAP on ultrasonography(8). Although the presence of vascular lakes is not significantly related with MAP, these structures are detected as intrauterine echolucent areas similar to lacunae. Color Doppler turbulent flow of the lacunae has also shown diagnostic value but there is no clear quantitative definition in this regard(9,10).
Despite advances in imaging modalities, there is no single diagnostic technique with 100% accuracy for predicting MAP because of variability across the studies. In this study, we quantitatively defined ultrasound findings and evaluated their accuracy in predicting MAP.
In this prospective cohort study, all the consecutive patients with anterior placenta and a history of at least one previous cesarean section who were referred to the Ghaem hospital, Mashhad, Iran, for routine prenatal screening by ultrasound between 2020 and 2021 were evaluated. All the enrolled patients signed written informed consent forms. The exclusion criteria were patients who did not observe their follow-up appointment sessions and those who gave birth in other hospitals. The study was approved by Ethics Committee of Mashhad University of Medical Sciences (approval number 971407).
Ultrasound evaluations were performed using a Medison V20 unit and a 5 MHz probe to assess the presence and extent of echolucent zones within the placenta. To examine the diagnostic value of the echolucent area, the number and maximum size of echolucent zones at different sites of the placenta were measured and recorded in each case using grayscale and color Doppler ultrasound. The echolucent zone was defined as any echolucent area >5×5 mm, including the venous lake or lacuna. The vessels were defined as blood vessels traversing more than 50% of the placental thickness. The number of detected echolucent zones was measured at various placental sites including the intraplacental (enclosed in the placenta), non-fetal surface (between uterus and placenta), fetal surface, fetal to non-fetal extended, and total (sum of all the detected echolucent zones in any part of the placenta) in each patient.
We also examined all the patients by color Doppler ultrasound. To adjust the color box (region of interest), the color gain was set at the highest level without any aliasing artifact, and the pulse repetition frequency (PRF) was also set at 11–14 cm/s. After adjusting the color box and color gain, the number of echolucent zones with blood flow, vessels, and vascularity of the posterior placenta was measured (Fig. 1).
All the patients were referred to a gynecologist and delivered at the Ghaem hospital. The presence or absence of adhesions during delivery was recorded by a surgeon. In cases with cesarean section or hysterectomy, data regarding the type of adhesion (accreta, increta or percreta) were recorded according to pathology. Ghaem Hospital Information System (HIS) was used to retrieve relevant information on patients’ maternity.
The independent t-test was used to compare the quantitative variables with normal distribution, and the Mann-Whitney test was employed to compare the non-normally distributed quantitative variables. The chi-square or Fisher’s test was used to compare the qualitative variables. A
A total of 120 pregnant women gave birth at the Ghaem hospital during the study period. MAP was detected in 15 out of 120 cases. Patients had a mean age of 33.47 ± 4.7 years (range: 23–43). The median of the numbers of previous cesarean sections and abortions were 2 and 0, respectively.
Based on the pathology report, cases with MAP included four subjects with placenta accreta (26.6%), seven subjects with placenta increta (46.6%), and four subjects with placenta percreta (26.6%). Twelve cases with MAP had a cesarean section with hysterectomy (80%), and three patients had cesarean section without hysterectomy (20%). The placenta was attached to the uterus in 11 cases (73.3%), and to the bladder in four cases (26.6%).
There was a significant difference between two groups (i.e. cases with MAP compared to cases without MAP) regarding the number of vessels in the placenta, size and number of echolucent zones with/without color flow at various sites, including the fetal surface (
Comparison of the two study groups regarding the number of vessels in the placenta, size and number of echolucent zones with/without color flow at different sites
Variables | Patients with morbidly adherent placenta (mean ± SD) | Patients without morbidly adherent placenta (mean ± SD) | |
---|---|---|---|
Size of the largest echolucent areas at the fetal surface (mm) | 21.3 ± 8.1 | 15.42 ± 11.68 | 0.001 |
Size of the largest echolucent areas at the non-fetal surface (mm) | 19.4 ± 7.04 | 9.21 ± 10.64 | <0.001 |
Size of the largest echolucent areas extended to both surfaces (mm) | 21 ± 15.3 | 7.77 ± 14.41 | <0.001 |
Size of the largest echolucent areas enclosed in placenta (mm) | 16.93 ± 7.34 | 11.63 ± 7.60 | 0.01 |
Size of the largest echolucent area at any site (mm) | 29.4 ± 8.4 | 21.66 ± 12.83 | 0.004 |
Number of echolucent areas at the fetal surface | 4.86 ± 2.89 | 2.49 ± 2.08 | <0.001 |
Number of echolucent areas at the non-fetal surface | 3.53 ± 3.39 | 1.11 ± 1.29 | <0.001 |
Number of echolucent areas extended to both surfaces | 1.0 ± 0.84 | 0.40 ± 0.87 | 0.001 |
Number of echolucent areas enclosed in placenta | 9.06 ± 2.40 | 5.10 ± 4.26 | <0.001 |
Total number of intraplacental echolucent areas* | 18.40 ± 6.78 | 9.12 ± 6.45 | <0.001 |
Number of echolucent areas with flow at the fetal level | 1.86 ± 1.55 | 0.06 ± 0.28 | <0.001 |
Number of echolucent areas with flow at the non-fetal level | 1.4 ± 1.24 | 0.08 ± 0.39 | 0.01 |
Number of echolucent areas with flow extended to both surfaces | 0.73 ± 0.70 | 0.04 ± 0.25 | <0.001 |
Number of echolucent areas with flow enclosed in placenta | 4.33 ± 5.12 | 0.06 ± 0.31 | <0.001 |
Total number of intraplacental echolucent areas with flow* | 7 ± 3.6 | 0.24 ± 0.76 | <0.001 |
Number of vessels in placenta | 5.53 ± 1.68 | 2.39 ± 2 | <0.001 |
* Sum of all the detected echolucent zones in any part of the uterine
The diagnostic accuracy of the number of echolucent zones at the intraplacental, fetal, non-fetal, fetal to non-fetal extended surfaces and sum of all the detected echolucent zones in any part of the placenta in predicting MAP was measured using ROC curve analysis. The total number of echolucent zones had the largest ROC AUC (AUC = 0.85).
ROC curve diagram and AUC related to the diagnostic accuracy of the largest size of echolucent zones at different sites in predicting MAP was also measured. The size of the largest echolucent zone at non-fetal site had the highest AUC (AUC = 0.80).
The ROC curve regarding the accuracy of the number of echolucent zones with color flow at different evaluated sites was measured as well. The number of echolucent zones with color flow at the fetal and non-fetal surfaces had an AUC >0.80. However, the total number of echolucent zones with flow (sum of the number of echolucent zones at all the evaluated surfaces) had an AUC = 0.99.
Table 2 summarizes the cut-off values of the ultrasound criteria with the highest AUC as well as estimated sensitivity and specificity. Figure 2 shows the ROC curve of ultrasound criteria with the highest diagnostic accuracy for predicting MAP. The total number of echolucent zones with color flow had the highest AUC.
Sensitivity and specificity of echolucent areas in predicting morbidly adherent placenta
Variables | Amount | Sensitivity | Specificity |
---|---|---|---|
Total number of intraplacental echolucent areas with flow | >2 | 0.93 | 0.98 |
Total number of intraplacental echolucent areas | >13 | 0.86 | 0.80 |
Size of the largest echolucent area in non-fetal part | >11 | 0.93 | 0.66 |
Early antenatal detection of MAP is vital for guiding maternal counseling, managing the delivery plans, and reducing the associated risk of maternal and fetal morbidity and mortality. In this study, the predictive accuracy of ultrasonographic criteria in detecting MAP was evaluated. In some previous studies, vascular lacunae, loss of the normal hypoechoic retroplacental zone, abnormal vessels at the bladder-myometrium interface, and bladder invasion were the examined ultrasonographic criteria for predicting the incidence of MAP(8,12). However, in the present study, we evaluated these ultrasound criteria quantitatively. The diagnostic criteria included the number and size of echolucent areas at different locations as well as the number of detected vessels. The predictive value of these diagnostic criteria was assessed quantitatively, and the cut-off value was also measured for these factors.
Results of the current study showed that more than two echolucent zones with flow (by color Doppler ultrasound) in the placenta had the highest sensitivity and specificity (93% and 98%, respectively) in diagnosing MAP. Similarly, more than 13 echolucent zones in the placenta has gained the highest sensitivity and specificity in predicting MAP based on grayscale ultrasound (86% and 80%, respectively). Gao
The relationship between echolucent areas and the incidence of MAP was assessed quantitatively in a similar study that showed all the patients with placenta percreta to have more than six lacunae with turbulent flow(9). Some other research groups also reported a strong association between the number of intraplacental echolucent areas and the incidence of MAP. The frequency of diffuse lacunar flow pattern was reported to be linked to the prediction of adherent placenta. Based on these studies, the presence of numerous intraparenchymal lacunar vascular spaces within the placenta is a separate risk criterion for placenta accreta and these findings are consistent with our results(14–19).
Our results were also consistent with the study by Tovbin
Based on the findings, the size of the largest echolucent zone at non-fetal surface was a significant predictor of MAP. At the non-fetal surface, the size of the largest echolucent zone >11 mm had 93% sensitivity in predicting the incidence of MAP with 66% specificity, which was considerably low compared to the number of echolucent zones.
In the study by Calì
Previous investigations have evaluated the diagnostic value of gray-scale ultrasound in predicting MAP. The presence of placental lacunae has been suggested as one of the most significant criterion in grayscale ultrasound for predicting MAP; however, the highest reported sensitivity was 82.72%(22,24,25). In our study, more than 13 echolucent areas at the intrauterine level based on grayscale ultrasound were representative of MAP with the sensitivity and specificity of 86% and 80%, respectively.
The use of accurate and reproducible definitions for echolucent areas in the placenta with/without flow is one of the strengths of this study. Another strength is that we evaluated the accuracy of the size of echolucent zones and their number as well as their color flow at different sites of placenta in predicting MAP. However, our research also had certain limitations. The number of patients with confirmed MAP was low, so further studies with larger sample sizes and longer periods of study time are recommended.
According to the results obtained in the study, quantitative ultrasonographic criteria, including the number of echolucent zones with/ without flow and the size of the largest echolucent zone, showed significant sensitivity and specificity in diagnosing MAP.